A flurry of congressional activity brings hope of 340B reform. Meanwhile, BIO comments on clinical trial reform. (665 words, 2 minutes, 40 seconds) Congress shows renewed interest in 340B reform ...
Letters, Testimony and Comments BIO Comments on OMB Proposed Rule "Regulation for Federal Financial Assistance" July 13, 2026 Download Full Comments Below BIO Comments to OMB Download Discover More ...
At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the ...
Beijing CorreGene Biotechnology Co., Ltd., founded by several Peking University alumni, dedicated to the development of innovative therapeutics based on T-cell receptors (TCRs). CorreGene has ...
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the ...
WASHINGTON D.C. – Today, the Biotechnology Innovation Organization (BIO), in partnership with Kearney, a global management consulting firm, released a first-of-its-kind report that assesses the ...
John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary ...
The Biotechnology Innovation Organization has honored two biotechnology leaders who are driving cutting-edge breakthroughs in agricultural, environmental and industrial biotechnology. Dr. Pam Marrone, ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement. “The passage of the Mikaela Naylon Give Kids a Chance Act is ...
Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented ...
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results